Cancer Flashcards
What are the charcteristics of cancer cells?
- Uncontrolled cellular growth
- Ability to invade adjacent structures and/or travel to distant areas
- Incapable of physiological functions of the mature tissue of origin
- Altered protein, enzymes systems, membrane characteristics and cytogenetics
TMN staging
- TMN staging for solid tumors
- Tumor
- Nodal status
- Metastasis
What does adjuvant chemotherapy mean? neoadjuvant chemotherapy?
adjuvant chemotherapy- giving chemo after surgery to reduce the risk of local and systemic recurrence
neoadjuvant chemotherapy- giving chemo prior to surgical intervention to reduce tumor size and to remove micrometastases
Cytotoxic chemotherapy
Toxic to all cells but specifically to those that are rapidly dividing cells
Wht does doubling time mean? Gompertizian growth? Log-kill hypothesis?
- Doubling time- time it takes for tumor cell production to double in size
- Gompertizian growth- early growth is exponential, but as tumor gets bigger, growth slows due to decreased nutrients/ blood supply
- Log-kill hypothesis- a given dose of chemotherapy kills the same fraction of tumor cells regardless of the size of the tumor at the time of treatment
Cytotoxic dosing? Dose intensity vs dose density?
Dosing- weight based dose, actual weight
Dose density- want to give same amount of chemo at scheduled time
Dose intensity- compress dosing time as short as possible (more chemo in short period of time)
MOA of alklating agents? class side effects?
MOA- prevents cell division by cross-linking DNA strands
Myelosupression is dose limiting toxicity
ADR- nausea/ vomitting, myelosupression, alopecia, sterility/ infertility, secondary malignancies
Cyclophosphamide/ Ifosfamide
Alklating agent
Hemorrhagic cystitis (bladder bleeding) due to acrolein metabolite
Give ifosfamide with Mesna (binds acrolein and excreted through the urine)
Cisplatin
Alkylating Agents
Causes- nephrotoxicity, nausea/vomitting, ototxicity
Oxaliplatin
Alkylating Agent
Neuropathies (exacerbated by cold temp)
MOA of antimetabolite? class side effects?
MOA- compete with normal metabolite or falsely insert themselves for a metabolite normally incororated into DNA and RNA. Nucleotide synthesis. Works on S phase
ADR- myelosuppression, mucosities, mild N/V/D
Methotrexate (MTX)
Antimetabolite
Renal toxicity (do not give with Cisplatin)
Leucovorin rescue for high doses
Cytarabine
Antimetabolite
Cerebellar toxicity
Ocular irratation- use eye drops
Cepecitabine
Antimetabolite
Hand foot syndrome
MOA of antitumor antiboitics? anthracyclines? Bleomycin? Class ADR?
anthracyclines- block DNA and RNA transcription
Bleomycin- inhibits DNA synthesis (only cell cycle specific agent)
ADR- N/V, alopecia, stomatitis, myelsupression
Bleomycin
Antitumor antiboitc- lung toxicity, pulmonary fibrosis, interstitial pneumonities
Anthracyclines
Doxarubicin- cardiotoxic-CHF
Life time max dose
Dexrazoxane- used to reduce cardiotoxicity with anthracylibes
Taxanes and vinca alkaloids MOA?
Taxanes- prevent microtubule disassembly
vinca alkaloids- prevent microtubule formation
Both workin M phase
Docetaxel and Pactitaxel
- Docetaxel- neuropathies, peripheral edema, hypersensitive reactions (due to solubilizing agents)
- Pactitaxel- neuropathies, hypersensitive reactions (due to solubilizing agents)
- premedicate with H1 and H2 blockers plus steroids
Vincristin
Vinca alkaloid,
neuropathy, constipation DO NOT GIVE INTRATHECALLY (DEADLY)
Irinotecan
Prevent DNA repair in cancer cells
Topoisomerase 1 inhibitor- diarrhea (cholinergic reaction)
Treat with atropine loperamide
Etoposide
Prevent DNA repair in cancer cells
Topoisomerase II inhibitor- secondary cancer
Asparaginase
Prevent DNA repair in cancer cells
Enzyme- natural product
Hypersensitivity reactions, hyperglycemia, pancreatitis, coagulopathy
Marine based products- Eribulin and Trabectedin
- Eribulin-
- sea sponge
- microtubule like agent
- toxicities- fatigue peripheral neuropathies, N/V
- Trabectedin
- Sea squirt
- alkylating agent
- toxicities- fatigue, hand-foot mouth syndrome, N/V, hepatic damage
Tamoxifen
SERM
Pre/ Post menopausal women
ADR- contracts, endometrial cancer, VTE, *CYP269 active metabolitle* INTERACTION WITH SSRI
Letrozole, anatrozole, exemestane
Aromatase inhibitors- inhibits the conversion of androgens to estrogens
Postmenopasual women (preferred)
ADR- osteoporosis, factures, arthralgias
Raloxifene
NOT USED FOR THE TREATMENT OF BREAST CANCER
only for primary prevenetion
Leuprolide, goserelin, triptorelin
LHRH agonist- inhibit the pituitary (through negative feedback) from relasing LH and FSH which stops stimulation of the testes to produce testoserone (can also be used in breast cancer with same MOA but stops stimuation of ovaries to produce estrogen)
Initially there is a tumor flare before negative feedback loop works
Degarelix
LHRH antagonist- directly inhibits pituatary from realeasing LH and FSH
Bicalutamide, flutamide, nilutamide, enzalutamide, apalutamide, abiraterone
Anti- androgen- blocks androgen recepotors only
Only for prostate cancer
MOA of targeted therapy? Monoclonal antibodies and molecularly targeted therapy? Class ADR?
MOA- prevent tumor cells from entering cell cycle or target signals that trigger cancer growth, metastasis and immortaility
Monoclonal antibodies- antibodies that match an antigen on the cencer cell surface molecularly targeted therapy- block signaling inside the cell
ADR- fatigie, hair thining, N/V, myelosupression, hair dipigmentation, dysphonia, hypothyroidism
QT prolongation- nitotinib, pazopanib, ponatinib
VEGF(R) inhibitor- bevacizumab, sunitinab, pazapanib, regorafenib
Inhibit formation of new blood vessles
ADR- hypertension, proteinuria, bleeding, impaired wound healing
EGFR inhibitors- erlotinib, gefitinib, alectinib, cetuximab, panitumumab
Acneiform rash
Rash indicates the treatment is working
Treatment- tetracyclines, topical antiboitics
mTOR inhibitors- everolimus, sirolimus, temsirolimus
ADR- hyperglycemia, dyslipidemia, mucosal sensitivity, Ulcers
DDI- 3A4 inhibitor
Treat ulcers with- dexamethasone s/s
BCR-ABL mutation
Periorbital edema
CYP 3A4 substates
CD20- rituximab, ofatumumab, obinutuzumab
Targeted B cell therapy for lymphoma, and leukemia
Infusion reactions, myelosupression
HER2 inhibition- Trastuzmab, pertuzumab
cardiotoxicity
do not give same time as anthyrcyclines
HER2 inhbition- lapatinib
ADR- Fatigue, diarrhea, hand-foot syndrome, drug interactions with strong 3A4 inducers/ inhibitors